암세포에 대한 기능 및/또는 유전체 특성과 함께 감수성 분석 결과를 다음과 같은 방식으로 활용할 수 있습니다.

Live-cell-based CRO services we offer

Service Options

Drug Development Stage

Results

Process

01.
Immunophenotyping & genotyping

01. Immunophenotyping & genotyping

• Drug screening
• Pre-clinical
• Phases I, II, and III

• Flow cytometry
• PCR for antigen receptor rearrangements (PARR)
• Gene mutations or expressions
• Immunophenotyping + genotyping report including prognostic information

Immunophenotyping
Assay

02.
Ex vivo drug sensitivity test

02. Ex vivo drug sensitivity test

• Drug screening
• Pre-clinical
• Phases I, II, and III

• Ex vivo sensitivity of the new drug compound(s) on patients’ live cancer cells
• AI-driven drug response prediction scores for conventional drugs
• Time-course efficacy and prognosis prediction for a gold standard combinatorial protocol

Immunophenotyping
Assay

Drug Sensitivity Assay

03.
Responder vs. Non-responder profiling

03. Responder vs. Non-responder

• Pre-clinical
• Phases I

• Refined inclusion criteria for clinical trials based on responding patients’:

• Immune subtypes (antigen expression profiles using 10+ antibodies)
• Ex vivo responses against the new drug compound(s) and the drug panel
• Naive/relapse and signalment information, etc.

Immunophenotyping
Assay

Drug Sensitivity Assay

Data Analysis (Population-based)

04.
Identification of synergistic combination

04. Identification of synergistic combination

• Pre-clinical
• Phases I

• Live-cell based, ex vivo population study data investigate new drug combinations between the existing drugs and the new drug compound(s)
• Mechanism of action analysis
• New target(s) identification

Immunophenotyping
Assay

Drug Sensitivity Assay

Data Analysis (Population-based)

05.
Response predictions for individual patients

05. Response predictions for individual patients

• Phases II and III

• All the above results throughout the life of the clinical study or trial
• Development of a companion diagnostic AI model that predicts clinical response and prognosis of the new drug compound
• Adding the new drug(s) to the drug panel in ImpriMed’s commercial services

Immunophenotyping
Assay

Drug Sensitivity Assay

Model Development
& Data Analysis
(Personalized)

상기 서비스는 AML 혹은 NHL을 대상으로 하는 약물 후보에 대해 제공 가능합니다.
보다 자세한 문의는 imprimedkorea@imprimedicine.com를 통해 제공해 드리겠습니다.

AI-Driven CRO services we offer

Service Options

Results

Process

01.
Statistical analysis of your datasets

01. Immunophenotyping & genotyping

• Hypothesis testing
• Survival analysis
• Univariate, multivariate analysis
• Comparative analysis

Statistical Analysis

02.
Machine learning model development

02. Ex vivo drug sensitivity test

• Includes statistical analysis
• Preprocessing of the datasets
• Development of machine learning models
• Cross-fold validation of the models

Statistical Analysis

ML Model Development

03.
Validation of machine learning models

03. Responder vs. Non-responder

• Includes statistical analysis
• Independent validation of your machine learning model performance
• Perform test using independent datasets from other institutions

Statistical Analysis

ML Model Development

ML Model Testing

04.
Commercialization of your machine learning model

05. Response predictions for individual patients

• Includes validation of the ML model(s)
• Have your ML models be commercially available

Statistical Analysis

ML Model Development

ML Model Testing

Productionization